Tenofovir may reduce risk of liver cancer in patients with HBV infection

the ONA take:

A new study published online ahead of print in the journal Cancer has shown that long-term therapy with tenofovir disoproxil fumarate (TDF) was associated with a decreased incidence of hepatocellular carcinoma among patients with chronic hepatitis B virus (HBV) infection without cirrhosis.

According to the American Cancer Society, there will be nearly 36,000 new cases of liver cancer diagnosed in the 2015 and about 24,550 people will die from the disease.

For the study, researchers analyzed data from the pivotal TDF registration studies that followed patients for 384 weeks. Of the 634 patients included for analysis, 152 had cirrhosis and 482 did not. During the study period, 14 patients developed hepatocellular carcinoma.

Results showed that the incidence of hepatocellular carcinoma was significantly lower than predicted among patients without cirrhosis.

TDF is an oral antiviral medication used to treat HIV infection in combination with other drugs and chronic HBV infection.

Tenofovir may reduce risk of liver cancer in patients with HBV infection
Long-term therapy with tenofovir was associated with a decreased incidence of HCC among patients with chronic HBV infection without cirrhosis.
Efficacy trials have shown that antiviral therapy improves the outcomes of patients with chronic HBV infection. However, prospective data regarding the effect of antiviral therapy on the incidence of HCC, especially among patients without cirrhosis, are limited.
READ FULL ARTICLE From Wiley Online Library
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs